RT Journal Article
SR Electronic
T1 Genome-wide association study implicates novel loci and reveals candidate effector genes for longitudinal pediatric bone accrual through variant-to-gene mapping
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.17.20024133
DO 10.1101/2020.02.17.20024133
A1 Diana L. Cousminer
A1 Yadav Wagley
A1 James A. Pippin
A1 Ahmed Elhakeem
A1 Gregory P. Way
A1 Shana E. McCormack
A1 Alessandra Chesi
A1 Jonathan A. Mitchell
A1 Joseph M. Kindler
A1 Denis Baird
A1 April Hartley
A1 Laura Howe
A1 Heidi J. Kalkwarf
A1 Joan M. Lappe
A1 Sumei Lu
A1 Michelle Leonard
A1 Matthew E. Johnson
A1 Hakon Hakonarson
A1 Vicente Gilsanz
A1 John A. Shepherd
A1 Sharon E. Oberfield
A1 Casey S. Greene
A1 Andrea Kelly
A1 Deborah Lawlor
A1 Benjamin F. Voight
A1 Andrew D. Wells
A1 Babette S. Zemel
A1 Kurt Hankenson
A1 Struan F. A. Grant
YR 2020
UL http://medrxiv.org/content/early/2020/02/20/2020.02.17.20024133.abstract
AB Bone accrual impacts lifelong skeletal health, but genetic discovery has been hampered by cross-sectional study designs and uncertainty about target effector genes. Here, we captured this dynamic phenotype by modeling longitudinal bone accrual across 11,000 bone scans followed by genome-wide association studies (GWAS). We revealed 40 loci (35 novel), half residing in topological associated domains harboring known bone genes. Variant-to-gene mapping identified contacts between GWAS loci and nearby gene promoters, and siRNA knockdown of gene expression clarified the putative effector gene at three specific loci in two osteoblast cell models. The resulting target genes highlight the cell fate decision between osteogenic and adipogenic lineages as important in normal bone accrual.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by R01 HD58886; the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) contracts (N01-HD-1-3228, -3329, -3330, -3331, -3332, -3333); and the CTSA program Grant 8 UL1 TR000077. D.L.C. is supported by NIH/NICHD grant 1K99HD099330-01. J.M. is supported by NIH/NHLBI grant K01HL123612. S.F.A.G. is supported by the Daniel B. Burke Endowed Chair for Diabetes Research and R01 HG010067. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBMDCS data can be applied for and downloaded via the NIH Data and Specimen Hub (https://dash.nichd.nih.gov/). ALSPAC data is also available on request at http://www.bristol.ac.uk/alspac/researchers/access/.